MicroRNA-647 (miR-647)

MicroRNA-647 (miR-647) is a conserved, ~22 nucleotide, single-stranded RNA from the microRNA family found in humans and other animals[1][4][5]. It is encoded by two homologous loci on chromosome 20q13.33, with mature forms hsa-miR-647-5p and hsa-miR-647-3p[1]. miR-647 is a post-transcriptional regulator, mainly binding its target mRNAs via partial complementarity in the 3’-UTR, leading to degradation or inhibition of translation[2][5]. It is implicated in key regulatory pathways including the cell cycle, apoptosis, PI3K, JAK/STAT, MAPK, GPCR signaling, and chromatin organization[1][2][5]. In cancer, miR-647 may function either as a tumor suppressor or oncomiR, depending on context, with aberrant levels detected in multiple malignancies[1][2]. It is proposed as both a biomarker for diagnosis/prognosis and a potential therapeutic target, with its serum/tissue levels correlated to disease outcome and therapy response[1]. MicroRNA-647 is not a protein, receptor, enzyme, or ion channel; it is a regulatory RNA molecule (microRNA) that controls gene expression at the RNA level[1][3][5]. It is considered a promising therapeutic target in oncology, primarily due to its role in tumor biology and potential as a biomarker[1][2]. No specific approved drugs directly interact with miR-647, but modulation of its levels is an active area of research in therapeutic development[1][2].

Other names

hsa-mir-647MIR647MIRN647

Drugs or therapeutic approaches may act by increasing or decreasing miR-647 expression or modulating its downstream target genes (e.g., TRAF2, NFIX, TP73). Indirect inhibition or restoration of miR-647 function through oligonucleotide therapeutics (mimics or antagomiRs).